

Aman P Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3298776/publications.pdf>

Version: 2024-02-01

14
papers

498
citations

759233

12
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

415
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 567-582.	1.8	81
2	Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs, 2020, 12, 1688616.	5.2	71
3	Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor T Cells in Humans. Clinical Pharmacology and Therapeutics, 2021, 109, 716-727.	4.7	49
4	Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition. AAPS Journal, 2015, 17, 389-399.	4.4	47
5	Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development. Pharmaceutical Research, 2015, 32, 3508-3525.	3.5	44
6	Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS Journal, 2016, 18, 861-875.	4.4	37
7	Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation. AAPS Journal, 2020, 22, 28.	4.4	32
8	Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). AAPS Journal, 2017, 19, 1054-1070.	4.4	31
9	Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE. Drug Metabolism and Disposition, 2017, 45, 1120-1132.	3.3	31
10	Benchmark bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 362-376.	2.5	23
11	Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and <i>In Vivo</i> Bystander Effect. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 184-199.	2.5	20
12	A Dual-Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC. Journal of Pharmaceutical Sciences, 2019, 108, 2465-2475.	3.3	16
13	A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs. Pharmaceutics, 2019, 11, 98.	4.5	12
14	Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development. Cancer Drug Discovery and Development, 2018, , 73-97.	0.4	3